###begin article-title 0
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">S&#8414;</xref>
Regulation of C-type Lectin Antimicrobial Activity by a Flexible N-terminal Prosegment*Sâƒž
###end article-title 0
###begin p 1
Both authors contributed equally to this work.
###end p 1
###begin p 2
###xml 15 67 15 67 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Helen Hay Whitney Foundation Postdoctoral Fellowship</grant-sponsor>
Supported by a Helen Hay Whitney Foundation Postdoctoral Fellowship.
###end p 2
###begin p 3
###xml 15 29 15 29 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Chilton Fellow</grant-sponsor>
Supported as a Chilton Fellow.
###end p 3
###begin p 4
###xml 92 124 92 124 <email xmlns:xlink="http://www.w3.org/1999/xlink">kevin.gardner@utsouthwestern.edu</email>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 219 249 219 249 <email xmlns:xlink="http://www.w3.org/1999/xlink">lora.hooper@utsouthwestern.edu</email>
 To whom correspondence may be addressed: 5323 Harry Hines Blvd., Dallas, TX 75390. E-mail: kevin.gardner@utsouthwestern.edu. 5 To whom correspondence may be addressed: 5323 Harry Hines Blvd., Dallas, TX 75390. E-mail: lora.hooper@utsouthwestern.edu.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 5
###begin p 6
 applies to Author Choice Articles
###end p 6
###begin p 7
###xml 453 460 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 339 344 <span type="species:ncbi:9606">human</span>
Members of the RegIII family of intestinal C-type lectins are directly antibacterial proteins that play a vital role in maintaining host-bacterial homeostasis in the mammalian gut, yet little is known about the mechanisms that regulate their biological activity. Here we show that the antibacterial activities of mouse RegIIIgamma and its human ortholog, HIP/PAP, are tightly controlled by an inhibitory N-terminal prosegment that is removed by trypsin in vivo. NMR spectroscopy revealed a high degree of conformational flexibility in the HIP/PAP inhibitory prosegment, and mutation of either acidic prosegment residues or basic core protein residues disrupted prosegment inhibitory activity. NMR analyses of pro-HIP/PAP variants revealed distinctive colinear backbone amide chemical shift changes that correlated with antibacterial activity, suggesting that prosegment-HIP/PAP interactions are linked to a two-state conformational switch between biologically active and inactive protein states. These findings reveal a novel regulatory mechanism governing C-type lectin biological function and yield new insight into the control of intestinal innate immunity.
###end p 7
###begin p 8
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 8
###begin p 9
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 94 86 94 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">DK070855</grant-num>
###xml 110 118 110 118 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">GM081875</grant-num>
###xml 138 146 138 146 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">CA130441</grant-num>
###xml 198 227 198 227 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Burroughs Wellcome Foundation</grant-sponsor>
###xml 254 289 254 289 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Pathogenesis of Infectious Diseases</grant-sponsor>
###xml 319 345 319 345 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Robert A. Welch Foundation</grant-sponsor>
###xml 510 523 510 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants DK070855 (to L. V. H.), GM081875 (to K. H. G.), and CA130441 (to C. L. P.). This work was also supported by the Burroughs Wellcome Foundation (New Investigators in the Pathogenesis of Infectious Diseases Award (to L. V. H.), and the Robert A. Welch Foundation (I-1659, to L. V. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
The on-line version of this article (available at ) contains supplemental Figs. S1-S3.
###end p 10
###begin p 11
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
The gastrointestinal tracts of mammals are heavily colonized with vast symbiotic microbial communities and are also a major portal of entry for bacterial pathogens. To cope with these complex microbial challenges, intestinal epithelial cells produce a diverse repertoire of protein antibiotics from multiple distinct protein families (1). These proteins are secreted apically into the luminal environment of the intestine where they play a pivotal role in protecting against enteric infections (2, 3) and may also function to limit opportunistic invasion by symbiotic bacteria (4).
###end p 11
###begin p 12
###xml 259 260 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 355 356 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 474 475 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn6">6</xref>
###xml 513 514 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 581 582 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 686 687 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 689 690 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 809 810 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1034 1035 1018 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1489 1490 1469 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 496 501 <span type="species:ncbi:9606">human</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
We previously identified lectins as a novel class of secreted antibacterial proteins in the mammalian intestine. RegIIIgamma is a member of the RegIII subgroup of the C-type lectin family and is expressed in the small intestine in response to microbial cues (5), stored in epithelial cell secretory granules, and released into the small intestinal lumen (5). Similarly, HIP/PAP (hepatointestinal pancreatic/pancreatitis-associated protein; the human ortholog of RegIIIgamma)6 is expressed in the human intestine (6) and is up-regulated in patients with inflammatory bowel disease (7). These proteins are produced in multiple epithelial lineages, including enterocytes and Paneth cells (5, 6). Both RegIIIgamma and HIP/PAP are directly bactericidal at low micromolar concentrations for Gram-positive bacteria (5), revealing a previously unappreciated biological function for mammalian lectins. The antibacterial functions of RegIIIgamma and HIP/PAP are dependent upon binding bacterial targets through interactions with peptidoglycan (5). As peptidoglycan is localized on surfaces of Gram-positive bacteria but is buried in the periplasmic space of Gram-negative bacteria, this binding activity provides a molecular explanation for the Gram-positive specific bactericidal effects of these lectins. Although the mechanism of lectin-mediated antibacterial activity remains unclear, RegIIIgamma and HIP/PAP have been shown to elicit extensive damage to the cell surfaces of targeted bacteria (5).
###end p 12
###begin p 13
###xml 148 155 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
In this study, we show that C-type lectin bactericidal activity is under stringent post-translational control. RegIIIgamma and HIP/PAP each undergo in vivo proteolytic removal of a flexible anionic N-terminal prosegment that maintains the proteins in a biologically inactive state. NMR spectroscopy suggests that the prosegment functions by controlling a two-state conformational switch between the biologically active and inactive states of the protein. We propose that this regulatory mechanism allows the host to restrict expression of RegIII lectin antibacterial activity to the intestinal lumen. Together, our findings represent a unique example of post-translational control of C-type lectin biological activity, and provide novel insight into the regulation of lectin-mediated innate immunity in the mammalian intestine.
###end p 13
###begin title 14
EXPERIMENTAL PROCEDURES
###end title 14
###begin p 15
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Purification of Endogenous RegIII</italic>
###xml 345 346 337 338 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 363 364 355 356 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 469 470 461 462 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 488 489 480 481 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 516 517 508 509 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 535 536 527 528 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 762 763 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Purification of Endogenous RegIIIgamma-Endogenous RegIIIgamma was purified from the small intestines of C57BL/6 mice. Intestinal tissues were homogenized in 20% acetic acid solution containing protease inhibitors using a pre-chilled homogenization probe and lysed by sonication using a Misonix XL sonicator. The extract was dialyzed against 25 mm MES pH 5.0, 25 mm NaCl and was loaded onto a cation exchange column (SP-Sepharose, Sigma). The column was washed with 25 mm MES pH 5.0, 150 mm NaCl, and eluted with 25 mm MES pH 5.0, 500 mm NaCl. The eluate was concentrated and loaded onto a Sephacryl S-100 column (GE Healthcare). RegIIIgamma-containing fractions were identified by Western blot, pooled, and purified by passage over immobilized anti-RegIIIgamma (8). The eluate was concentrated, transferred to Immobilon P, and subjected to Edman degradation on an ABI494 sequencer (PE Biosystems) to determine the N-terminal sequence.
###end p 15
###begin p 16
###xml 0 51 0 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Expression and Purification of Recombinant Proteins</italic>
###xml 169 170 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 333 334 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 385 391 365 371 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CATATG</underline>
###xml 440 446 420 426 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGATCC</underline>
###xml 865 866 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 1538 1539 1518 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 1638 1639 1618 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
Expression and Purification of Recombinant Proteins-Recombinant pro-RegIIIgamma (rpro-RegIIIgamma) and rpro-HIP/PAP were expressed and purified as previously described (8). To generate the recombinant processed form of RegIIIgamma, a 417-bp amplicon was generated using the rpro-RegIIIgamma expression construct (pET3a-RegIIIgamma) (8) as template and the specific primers 5'-ATTGCGAGGCATATGAGCAGCTGCCCCAAGGGCTCCC-3' (forward) and 5'-CTATGGGGATCCCTAGGCCTTGAATTTGCAGACATAGGGT-3' (reverse). The forward primer contained an NdeI restriction site (underlined) for cloning into pET3a. The reverse primer contained the native stop codon followed by an engineered BamHI site (underlined). The amplicon was digested with NdeI and BamHI and ligated into NdeI/BamHI-digested pET3a (Novagen). Similarly, the rHIP/PAP expression construct was generated using pET3a-HIP/PAPmut (8) as template and specific primers 5'-ATTGCGAGGCATATGATTCGATGTCCAAAAGGCTCCAAG-3' (forward) and 5'-CTATGGTGATCATCAGTGAACTTTGCAGACATAGGGTAACC-3' (reverse). The forward primer contained an NdeI site (underlined) while the reverse primer contained a BclI site (underlined) after the native stop codon. The amplicon was digested with NdeI and BclI and ligated into NdeI/BamHI-digested pET3a. Point mutations were introduced into rpro-HIP/PAP using the QuikChange II Site-directed Mutagenesis kit (Stratagene) and specific primers harboring the desired mutations. Expression and purification of recombinant wild-type and mutant proteins was carried out as previously described (8). Antimicrobial assays and peptidoglycan binding assays were carried out as previously described (5). Proteins were stored at -20 degreesC for a maximum of 1 week prior to assay.
###end p 16
###begin p 17
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblotting</italic>
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 401 402 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 408 412 <span type="species:ncbi:9925">goat</span>
###xml 418 424 <span type="species:ncbi:9986">rabbit</span>
###xml 425 436 <span type="species:ncbi:3704">horseradish</span>
Immunoblotting-Intestinal extracts were prepared from wild-type C57BL/6 or MMP7-/- mice (Jackson Laboratories) as previously described (5). Extracts from human intestinal tissues were prepared by extraction in acetic acid as previously described (9). 20 mug of each extract was loaded onto 15% SDS-PAGE gels and blotted onto Immobilon P (Millipore). Blots were probed with anti-RegIIIgamma antiserum (8) and goat anti-rabbit-horseradish peroxidase (Amersham Biosciences), and were detected by chemiluminescence using the Pierce SuperSignal West Pico Chemiluminescent detection kit.
###end p 17
###begin p 18
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Vitro Trypsin Proteolytic Processing</italic>
###xml 103 109 <span type="species:ncbi:9913">bovine</span>
In Vitro Trypsin Proteolytic Processing-Recombinant pro-RegIIIgamma and pro-HIP/PAP were digested with bovine pancreatic trypsin (Sigma) at a 1:200 molar ratio of trypsin:lectin at 37 degreesC for 2 h. Proteins were immediately analyzed by SDS-PAGE on 15% gels, and were subjected to N-terminal Edman sequencing.
###end p 18
###begin p 19
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NMR Spectroscopy</italic>
###xml 57 73 57 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 192 194 192 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 292 294 292 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 295 296 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 407 408 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 420 422 416 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 425 427 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 434 435 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 656 657 645 646 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 668 670 657 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 672 674 661 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 699 700 688 689 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 717 718 706 707 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 748 750 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 795 797 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 826 828 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 57 78 <span type="species:ncbi:511693">Escherichia coli BL21</span>
NMR Spectroscopy-To prepare samples for NMR experiments, Escherichia coli BL21-CodonPlus (DE3)-RILP transformed with expression plasmids were grown in M9 minimal media containing 1 g/liter of 15NH4Cl for uniformly 15N-labeled samples, further substituting unlabeled glucose with 3 g/liter of 13C6-glucose for uniformly 15N/13C-labeled samples. RegIIIgamma and HIP/PAP were purified as previously described (8). Backbone 15N, 13C, and 1H chemical shift assignments of rpro-HIP/PAP were generated from triple resonance NMR data recorded at 25 degreesC using a cryoprobe-equipped Varian Inova 600 MHz spectrometer. Backbone assignments were made from a 300 mum sample of 15N/13C-labeled protein in 25 mm MES pH 5.5, 25 mm NaCl using standard methods (10). All spectra were processed using NMRPipe (11) and analyzed with NMRView (12).
###end p 19
###begin title 20
RESULTS
###end title 20
###begin p 21
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RegIII</italic>
###xml 12 59 8 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Is Proteolytically Processed by Trypsin in Vivo</italic>
###xml 147 148 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 475 482 435 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 787 789 739 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">27</sup>
###xml 850 851 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 844 851 796 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 910 912 862 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 981 983 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 987 989 939 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 997 998 949 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 991 998 943 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1079 1080 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1073 1080 1025 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1144 1146 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 1449 1456 1393 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 542 547 <span type="species:ncbi:10090">mouse</span>
###xml 1034 1039 <span type="species:ncbi:10090">mouse</span>
###xml 1044 1049 <span type="species:ncbi:9606">human</span>
###xml 1364 1369 <span type="species:ncbi:10090">mouse</span>
RegIIIgamma Is Proteolytically Processed by Trypsin in Vivo-Two distinct forms of endogenous RegIIIgamma are present in the mouse small intestine (5). The higher molecular weight form co-migrates at approximately16.5 kDa with recombinant RegIIIgamma that lacks its N-terminal secretion signal, while the lower molecular weight form migrates at approximately15 kDa. The presence of the lower molecular weight form suggested that RegIIIgamma might be proteolytically processed in vivo. To test this idea we purified endogenous RegIIIgamma from mouse small intestine by acid extraction, gel filtration chromatography, and antibody affinity chromatography. Edman sequencing of the purified proteins verified that the higher molecular weight RegIIIgamma form indeed harbors an N terminus (Glu27) that is generated by removal of the signal sequence (Fig. 1A). The N terminus of the lower molecular weight form is Ser38, corresponding to the predicted trypsin cleavage site located at Arg37-Ser38 (Fig. 1A). This site is conserved among all mouse and human RegIII family members (Fig. 1B), and is also present in other Reg subfamilies including RegI (13). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) of both RegIIIgamma forms did not reveal any further modifications of the protein (data not shown). These results indicate that the N terminus of endogenous mouse RegIIIgamma is proteolytically processed by trypsin or a trypsin-like protease in vivo.
###end p 21
###begin p 22
###xml 188 189 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 279 280 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 441 444 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 497 500 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 513 514 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 507 514 487 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 140 145 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:10090">mouse</span>
###xml 337 342 <span type="species:ncbi:10090">mouse</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
Small intestinal alpha-defensins are a distinct family of antimicrobial peptides that also undergo N-terminal proteolytic processing. While human alpha-defensins are processed by trypsin (9), the processing enzyme for mouse alpha-defensins is matrix metalloproteinase-7 (MMP-7) (2). To verify that MMP-7 is not the processing enzyme for mouse RegIIIgamma we performed Western blots on small intestinal tissue extracts from wild-type and MMP7-/- mice. Both RegIIIgamma forms were detectable in MMP7-/- mice (Fig. 1C), establishing that MMP-7 is dispensable for RegIIIgamma processing. Thus, RegIIIgamma and alpha-defensins are processed by distinct proteases in the mouse small intestine.
###end p 22
###begin p 23
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 61 68 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 9 69 9 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RegIII&#947; is proteolytically processed by trypsin <italic>in vivo</italic>.</bold>
###xml 69 70 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 204 205 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 254 259 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 472 473 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 573 576 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 633 634 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 649 656 632 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1060 1071 1038 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E, in vitro</italic>
###xml 1417 1419 1387 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 1423 1425 1393 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 1433 1435 1403 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 1439 1441 1409 1411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 9 1456 9 1426 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24"><bold>RegIII&#947; is proteolytically processed by trypsin <italic>in vivo</italic>.</bold><italic>A</italic>, purification and N-terminal sequencing of endogenous mouse RegIII&#947; reveals processing at the conserved N-terminal trypsin site. <italic>B</italic>, conserved canonical trypsin site (indicated by <italic>arrow</italic>) is present near the N terminus of mouse and human RegIII family members. Residue numbers are based on the deduced sequence which includes the signal peptide. Position 1 corresponds to the initiating methionine. <italic>C</italic>, MMP-7 is dispensable for RegIII&#947; processing. 20 &#956;g of protein extract from wild-type and MMP7<sup>&#8211;/&#8211;</sup> mice were immunoblotted with anti-RegIII&#947; antibody. <italic>D</italic>, evidence for <italic>in vivo</italic> proteolytic processing of HIP/PAP. 20 &#956;g of human intestinal protein extract was immunoblotted and probed with anti-RegIII&#947; antiserum. Recombinant pro-HIP/PAP (rpro-HIP/PAP; with the N-terminal signal sequence replaced by methionine) and recombinant processed HIP/PAP (rHIP/PAP; with the N-terminal tryptic fragment replaced by methionine) were included for size comparison. s.i., small intestinal <italic>E, in vitro</italic> incubation of purified recombinant pro-RegIII&#947; (rpro-RegIII&#947;) and rpro-HIP/PAP with bovine trypsin results in quantitative cleavage at the conserved trypsin site to yield a homogeneous product. Proteins were digested with a 1:200 molar ratio of trypsin:lectin and were analyzed by SDS-PAGE. N-terminal sequencing verified cleavage at Arg<sup>37</sup>&#8211;Ser<sup>38</sup> and Arg<sup>37</sup>&#8211;Ile<sup>38</sup>, respectively.</p>
###xml 9 1456 9 1426 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24"><bold>RegIII&#947; is proteolytically processed by trypsin <italic>in vivo</italic>.</bold><italic>A</italic>, purification and N-terminal sequencing of endogenous mouse RegIII&#947; reveals processing at the conserved N-terminal trypsin site. <italic>B</italic>, conserved canonical trypsin site (indicated by <italic>arrow</italic>) is present near the N terminus of mouse and human RegIII family members. Residue numbers are based on the deduced sequence which includes the signal peptide. Position 1 corresponds to the initiating methionine. <italic>C</italic>, MMP-7 is dispensable for RegIII&#947; processing. 20 &#956;g of protein extract from wild-type and MMP7<sup>&#8211;/&#8211;</sup> mice were immunoblotted with anti-RegIII&#947; antibody. <italic>D</italic>, evidence for <italic>in vivo</italic> proteolytic processing of HIP/PAP. 20 &#956;g of human intestinal protein extract was immunoblotted and probed with anti-RegIII&#947; antiserum. Recombinant pro-HIP/PAP (rpro-HIP/PAP; with the N-terminal signal sequence replaced by methionine) and recombinant processed HIP/PAP (rHIP/PAP; with the N-terminal tryptic fragment replaced by methionine) were included for size comparison. s.i., small intestinal <italic>E, in vitro</italic> incubation of purified recombinant pro-RegIII&#947; (rpro-RegIII&#947;) and rpro-HIP/PAP with bovine trypsin results in quantitative cleavage at the conserved trypsin site to yield a homogeneous product. Proteins were digested with a 1:200 molar ratio of trypsin:lectin and were analyzed by SDS-PAGE. N-terminal sequencing verified cleavage at Arg<sup>37</sup>&#8211;Ser<sup>38</sup> and Arg<sup>37</sup>&#8211;Ile<sup>38</sup>, respectively.</p></caption>
###xml 1456 1456 1426 1426 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420001"/>
###xml 0 1456 0 1426 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="24"><bold>RegIII&#947; is proteolytically processed by trypsin <italic>in vivo</italic>.</bold><italic>A</italic>, purification and N-terminal sequencing of endogenous mouse RegIII&#947; reveals processing at the conserved N-terminal trypsin site. <italic>B</italic>, conserved canonical trypsin site (indicated by <italic>arrow</italic>) is present near the N terminus of mouse and human RegIII family members. Residue numbers are based on the deduced sequence which includes the signal peptide. Position 1 corresponds to the initiating methionine. <italic>C</italic>, MMP-7 is dispensable for RegIII&#947; processing. 20 &#956;g of protein extract from wild-type and MMP7<sup>&#8211;/&#8211;</sup> mice were immunoblotted with anti-RegIII&#947; antibody. <italic>D</italic>, evidence for <italic>in vivo</italic> proteolytic processing of HIP/PAP. 20 &#956;g of human intestinal protein extract was immunoblotted and probed with anti-RegIII&#947; antiserum. Recombinant pro-HIP/PAP (rpro-HIP/PAP; with the N-terminal signal sequence replaced by methionine) and recombinant processed HIP/PAP (rHIP/PAP; with the N-terminal tryptic fragment replaced by methionine) were included for size comparison. s.i., small intestinal <italic>E, in vitro</italic> incubation of purified recombinant pro-RegIII&#947; (rpro-RegIII&#947;) and rpro-HIP/PAP with bovine trypsin results in quantitative cleavage at the conserved trypsin site to yield a homogeneous product. Proteins were digested with a 1:200 molar ratio of trypsin:lectin and were analyzed by SDS-PAGE. N-terminal sequencing verified cleavage at Arg<sup>37</sup>&#8211;Ser<sup>38</sup> and Arg<sup>37</sup>&#8211;Ile<sup>38</sup>, respectively.</p></caption><graphic xlink:href="zbc0110967420001"/></fig>
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
###xml 295 300 <span type="species:ncbi:10090">mouse</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 702 707 <span type="species:ncbi:9606">human</span>
###xml 1164 1170 <span type="species:ncbi:9913">bovine</span>
FIGURE 1.RegIIIgamma is proteolytically processed by trypsin in vivo.A, purification and N-terminal sequencing of endogenous mouse RegIIIgamma reveals processing at the conserved N-terminal trypsin site. B, conserved canonical trypsin site (indicated by arrow) is present near the N terminus of mouse and human RegIII family members. Residue numbers are based on the deduced sequence which includes the signal peptide. Position 1 corresponds to the initiating methionine. C, MMP-7 is dispensable for RegIIIgamma processing. 20 mug of protein extract from wild-type and MMP7-/- mice were immunoblotted with anti-RegIIIgamma antibody. D, evidence for in vivo proteolytic processing of HIP/PAP. 20 mug of human intestinal protein extract was immunoblotted and probed with anti-RegIIIgamma antiserum. Recombinant pro-HIP/PAP (rpro-HIP/PAP; with the N-terminal signal sequence replaced by methionine) and recombinant processed HIP/PAP (rHIP/PAP; with the N-terminal tryptic fragment replaced by methionine) were included for size comparison. s.i., small intestinal E, in vitro incubation of purified recombinant pro-RegIIIgamma (rpro-RegIIIgamma) and rpro-HIP/PAP with bovine trypsin results in quantitative cleavage at the conserved trypsin site to yield a homogeneous product. Proteins were digested with a 1:200 molar ratio of trypsin:lectin and were analyzed by SDS-PAGE. N-terminal sequencing verified cleavage at Arg37-Ser38 and Arg37-Ile38, respectively.
###end p 23
###begin p 24
###xml 52 59 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 60 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RegIII&#947; is proteolytically processed by trypsin <italic>in vivo</italic>.</bold>
###xml 60 61 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 195 196 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 245 250 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 463 464 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 564 567 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;/&#8211;</sup>
###xml 624 625 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 640 647 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1051 1062 1029 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E, in vitro</italic>
###xml 1408 1410 1378 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 1414 1416 1384 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 1424 1426 1394 1396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 1430 1432 1400 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
###xml 286 291 <span type="species:ncbi:10090">mouse</span>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 693 698 <span type="species:ncbi:9606">human</span>
###xml 1155 1161 <span type="species:ncbi:9913">bovine</span>
RegIIIgamma is proteolytically processed by trypsin in vivo.A, purification and N-terminal sequencing of endogenous mouse RegIIIgamma reveals processing at the conserved N-terminal trypsin site. B, conserved canonical trypsin site (indicated by arrow) is present near the N terminus of mouse and human RegIII family members. Residue numbers are based on the deduced sequence which includes the signal peptide. Position 1 corresponds to the initiating methionine. C, MMP-7 is dispensable for RegIIIgamma processing. 20 mug of protein extract from wild-type and MMP7-/- mice were immunoblotted with anti-RegIIIgamma antibody. D, evidence for in vivo proteolytic processing of HIP/PAP. 20 mug of human intestinal protein extract was immunoblotted and probed with anti-RegIIIgamma antiserum. Recombinant pro-HIP/PAP (rpro-HIP/PAP; with the N-terminal signal sequence replaced by methionine) and recombinant processed HIP/PAP (rHIP/PAP; with the N-terminal tryptic fragment replaced by methionine) were included for size comparison. s.i., small intestinal E, in vitro incubation of purified recombinant pro-RegIIIgamma (rpro-RegIIIgamma) and rpro-HIP/PAP with bovine trypsin results in quantitative cleavage at the conserved trypsin site to yield a homogeneous product. Proteins were digested with a 1:200 molar ratio of trypsin:lectin and were analyzed by SDS-PAGE. N-terminal sequencing verified cleavage at Arg37-Ser38 and Arg37-Ile38, respectively.
###end p 24
###begin p 25
###xml 94 95 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 97 99 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 148 149 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 358 365 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 373 374 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 367 374 363 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 651 653 647 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 657 659 653 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 689 690 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 683 690 679 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 743 750 739 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 941 948 937 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 950 951 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 962 970 958 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1129 1131 1125 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 1135 1137 1131 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 1145 1146 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1139 1146 1135 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 851 856 <span type="species:ncbi:9606">human</span>
###xml 1029 1035 <span type="species:ncbi:9913">bovine</span>
In the human small intestine, HIP/PAP is the predominantly expressed ortholog of RegIIIgamma (6, 14) and performs a similar antibacterial function (5). Immunoblotting of human small intestinal extract revealed two forms of HIP/PAP with different molecular weights, suggesting that HIP/PAP is also expressed as a pro-protein that is proteolytically processed in vivo (Fig. 1D). Although the small amounts of HIP/PAP present in human tissue presented an obstacle to purification and sequencing, we established that the lower molecular weight form co-migrates with recombinant HIP/PAP engineered to lack the 11 amino acids N-terminal to the predicted Arg37-Ile38 trypsin cleavage site (Fig. 1D). The idea that the HIP/PAP N terminus is processed in vivo by trypsin is supported by two additional observations. First, two trypsin isoforms are produced by human small intestinal epithelia and have been shown to process other intestinal proteins in vivo (9). Second, in vitro incubation of recombinant pro-HIP/PAP (rpro-HIP/PAP) with bovine trypsin (at a 1:200 molar ratio of enzyme to lectin) resulted in quantitative cleavage at Arg37-Ile38 (Fig. 1E).
###end p 25
###begin p 26
###xml 0 80 0 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Proteolytic Processing by Trypsin Activates RegIII Lectin Antimicrobial Activity</italic>
###xml 321 329 313 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 377 399 369 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes</italic>
###xml 434 435 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 516 532 504 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 582 583 569 570 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 608 609 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 602 609 585 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 702 718 681 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 769 770 747 748 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 802 803 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 796 803 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 904 905 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 898 905 872 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1034 1035 1007 1008 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1071 1087 1044 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 1130 1131 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1124 1131 1097 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 377 399 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 516 532 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 702 718 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 1071 1087 <span type="species:ncbi:1639">L. monocytogenes</span>
Proteolytic Processing by Trypsin Activates RegIII Lectin Antimicrobial Activity-We next investigated the biological relevance of lectin proteolytic processing. To test the hypothesis that processing regulates RegIII lectin antibacterial activity, we incubated recombinant pro-RegIIIgamma (rpro-RegIIIgamma) with trypsin in vitro and quantitated antimicrobial activity against Listeria monocytogenes in standard antibacterial assays (5). Mock-digested rpro-RegIIIgamma exhibited limited antibacterial activity, with L. monocytogenes numbers declining by 68% in the presence of 10 mum rpro-RegIIIgamma (Fig. 2A). However, trypsin-digested rpro-RegIIIgamma exhibited enhanced antibacterial potency, with L. monocytogenes numbers declining by >96% in the presence of 10 mum of digested RegIIIgamma (Fig. 2A). A comparison of proteolytically cleaved and uncleaved rpro-HIP/PAP yielded similar results (Fig. 2B). The enhanced activity of trypsin-cleaved HIP/PAP is not attributable to the N-terminal prosegment itself, as addition of 50 mum of synthetic N-terminal peptide to L. monocytogenes did not affect bacterial viability (Fig. 2C). These data demonstrate that removal of the N-terminal prosegment by trypsin enhances RegIIIgamma and HIP/PAP antibacterial activity.
###end p 26
###begin p 27
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 90 9 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.</bold>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 151 162 147 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rpro-RegIII</italic>
###xml 198 210 190 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rpro-HIP/PAP</italic>
###xml 273 274 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 294 295 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 343 344 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 337 344 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>e</italic></xref>
###xml 346 362 334 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 567 568 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 587 588 568 569 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 640 656 621 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 746 747 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 752 753 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1040 1041 1005 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1061 1062 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1065 1066 1030 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1137 1145 1102 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans</italic>
###xml 1200 1201 1165 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 9 1249 9 1214 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.</bold><italic>A</italic> and <italic>B</italic>, trypsin proteolysis of recombinant pro-RegIII&#947; (<italic>rpro-RegIII</italic>&#947;) and recombinant pro-HIP/PAP (<italic>rpro-HIP/PAP</italic>) activates antibacterial activity. Purified rpro-RegIII&#947; (<italic>A</italic>) and rpro-HIP/PAP (<italic>B</italic>) were digested with bovine trypsin as in <xref rid="fig1" ref-type="fig">Fig. 1<italic>e</italic></xref>. <italic>L. monocytogenes</italic> was exposed to the indicated lectin concentrations at 37 &#176;C for 2 h, and surviving bacteria were quantitated by dilution plating. An assay which included trypsin but no lectin was run as a control. <italic>C</italic>, addition of 50 &#956;<sc>m</sc> of the HIP/PAP N-terminal peptide did not diminish <italic>L. monocytogenes</italic> viability, indicating that the prosegment alone does not exhibit antibacterial activity. <italic>D</italic> and <italic>E</italic>, antibacterial activities of recombinant mature RegIII&#947; and HIP/PAP. The 11-amino acid prosegments of RegIII&#947; and HIP/PAP were removed and replaced with methionine to yield rRegIII&#947; and rHIP/PAP, and bactericidal activity was determined in comparison with rpro-RegIII&#947; (<italic>D</italic>) and rpro-HIP/PAP (<italic>E</italic>). <italic>F</italic>, HIP/PAP N-terminal prosegment does not inhibit bactericidal activity <italic>in trans</italic>. The synthetic HIP/PAP N-terminal peptide depicted in <italic>C</italic> was added to bactericidal assays with rHIP/PAP.</p>
###xml 9 1249 9 1214 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.</bold><italic>A</italic> and <italic>B</italic>, trypsin proteolysis of recombinant pro-RegIII&#947; (<italic>rpro-RegIII</italic>&#947;) and recombinant pro-HIP/PAP (<italic>rpro-HIP/PAP</italic>) activates antibacterial activity. Purified rpro-RegIII&#947; (<italic>A</italic>) and rpro-HIP/PAP (<italic>B</italic>) were digested with bovine trypsin as in <xref rid="fig1" ref-type="fig">Fig. 1<italic>e</italic></xref>. <italic>L. monocytogenes</italic> was exposed to the indicated lectin concentrations at 37 &#176;C for 2 h, and surviving bacteria were quantitated by dilution plating. An assay which included trypsin but no lectin was run as a control. <italic>C</italic>, addition of 50 &#956;<sc>m</sc> of the HIP/PAP N-terminal peptide did not diminish <italic>L. monocytogenes</italic> viability, indicating that the prosegment alone does not exhibit antibacterial activity. <italic>D</italic> and <italic>E</italic>, antibacterial activities of recombinant mature RegIII&#947; and HIP/PAP. The 11-amino acid prosegments of RegIII&#947; and HIP/PAP were removed and replaced with methionine to yield rRegIII&#947; and rHIP/PAP, and bactericidal activity was determined in comparison with rpro-RegIII&#947; (<italic>D</italic>) and rpro-HIP/PAP (<italic>E</italic>). <italic>F</italic>, HIP/PAP N-terminal prosegment does not inhibit bactericidal activity <italic>in trans</italic>. The synthetic HIP/PAP N-terminal peptide depicted in <italic>C</italic> was added to bactericidal assays with rHIP/PAP.</p></caption>
###xml 1249 1249 1214 1214 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420002"/>
###xml 0 1249 0 1214 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="28"><bold>Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.</bold><italic>A</italic> and <italic>B</italic>, trypsin proteolysis of recombinant pro-RegIII&#947; (<italic>rpro-RegIII</italic>&#947;) and recombinant pro-HIP/PAP (<italic>rpro-HIP/PAP</italic>) activates antibacterial activity. Purified rpro-RegIII&#947; (<italic>A</italic>) and rpro-HIP/PAP (<italic>B</italic>) were digested with bovine trypsin as in <xref rid="fig1" ref-type="fig">Fig. 1<italic>e</italic></xref>. <italic>L. monocytogenes</italic> was exposed to the indicated lectin concentrations at 37 &#176;C for 2 h, and surviving bacteria were quantitated by dilution plating. An assay which included trypsin but no lectin was run as a control. <italic>C</italic>, addition of 50 &#956;<sc>m</sc> of the HIP/PAP N-terminal peptide did not diminish <italic>L. monocytogenes</italic> viability, indicating that the prosegment alone does not exhibit antibacterial activity. <italic>D</italic> and <italic>E</italic>, antibacterial activities of recombinant mature RegIII&#947; and HIP/PAP. The 11-amino acid prosegments of RegIII&#947; and HIP/PAP were removed and replaced with methionine to yield rRegIII&#947; and rHIP/PAP, and bactericidal activity was determined in comparison with rpro-RegIII&#947; (<italic>D</italic>) and rpro-HIP/PAP (<italic>E</italic>). <italic>F</italic>, HIP/PAP N-terminal prosegment does not inhibit bactericidal activity <italic>in trans</italic>. The synthetic HIP/PAP N-terminal peptide depicted in <italic>C</italic> was added to bactericidal assays with rHIP/PAP.</p></caption><graphic xlink:href="zbc0110967420002"/></fig>
###xml 316 322 <span type="species:ncbi:9913">bovine</span>
###xml 346 362 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 640 656 <span type="species:ncbi:1639">L. monocytogenes</span>
FIGURE 2.Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.A and B, trypsin proteolysis of recombinant pro-RegIIIgamma (rpro-RegIIIgamma) and recombinant pro-HIP/PAP (rpro-HIP/PAP) activates antibacterial activity. Purified rpro-RegIIIgamma (A) and rpro-HIP/PAP (B) were digested with bovine trypsin as in Fig. 1e. L. monocytogenes was exposed to the indicated lectin concentrations at 37 degreesC for 2 h, and surviving bacteria were quantitated by dilution plating. An assay which included trypsin but no lectin was run as a control. C, addition of 50 mum of the HIP/PAP N-terminal peptide did not diminish L. monocytogenes viability, indicating that the prosegment alone does not exhibit antibacterial activity. D and E, antibacterial activities of recombinant mature RegIIIgamma and HIP/PAP. The 11-amino acid prosegments of RegIIIgamma and HIP/PAP were removed and replaced with methionine to yield rRegIIIgamma and rHIP/PAP, and bactericidal activity was determined in comparison with rpro-RegIIIgamma (D) and rpro-HIP/PAP (E). F, HIP/PAP N-terminal prosegment does not inhibit bactericidal activity in trans. The synthetic HIP/PAP N-terminal peptide depicted in C was added to bactericidal assays with rHIP/PAP.
###end p 27
###begin p 28
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.</bold>
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 142 153 138 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rpro-RegIII</italic>
###xml 189 201 181 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rpro-HIP/PAP</italic>
###xml 264 265 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 285 286 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 334 335 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 328 335 316 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>e</italic></xref>
###xml 337 353 325 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 558 559 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 578 579 559 560 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 631 647 612 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 737 738 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 743 744 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1031 1032 996 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1052 1053 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1056 1057 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1128 1136 1093 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans</italic>
###xml 1191 1192 1156 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 307 313 <span type="species:ncbi:9913">bovine</span>
###xml 337 353 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 631 647 <span type="species:ncbi:1639">L. monocytogenes</span>
Proteolysis of the N terminus by trypsin activates lectin antibacterial activity.A and B, trypsin proteolysis of recombinant pro-RegIIIgamma (rpro-RegIIIgamma) and recombinant pro-HIP/PAP (rpro-HIP/PAP) activates antibacterial activity. Purified rpro-RegIIIgamma (A) and rpro-HIP/PAP (B) were digested with bovine trypsin as in Fig. 1e. L. monocytogenes was exposed to the indicated lectin concentrations at 37 degreesC for 2 h, and surviving bacteria were quantitated by dilution plating. An assay which included trypsin but no lectin was run as a control. C, addition of 50 mum of the HIP/PAP N-terminal peptide did not diminish L. monocytogenes viability, indicating that the prosegment alone does not exhibit antibacterial activity. D and E, antibacterial activities of recombinant mature RegIIIgamma and HIP/PAP. The 11-amino acid prosegments of RegIIIgamma and HIP/PAP were removed and replaced with methionine to yield rRegIIIgamma and rHIP/PAP, and bactericidal activity was determined in comparison with rpro-RegIIIgamma (D) and rpro-HIP/PAP (E). F, HIP/PAP N-terminal prosegment does not inhibit bactericidal activity in trans. The synthetic HIP/PAP N-terminal peptide depicted in C was added to bactericidal assays with rHIP/PAP.
###end p 28
###begin p 29
###xml 191 192 186 187 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 252 268 239 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 352 353 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 346 353 329 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 372 373 354 355 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 488 489 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 482 489 464 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 538 546 520 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans</italic>
###xml 608 609 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 602 609 584 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>F</italic></xref>
###xml 688 694 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in cis</italic>
###xml 853 859 835 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 974 980 956 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in cis</italic>
###xml 252 268 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 807 812 <span type="species:ncbi:9606">human</span>
###xml 816 821 <span type="species:ncbi:10090">mouse</span>
To further establish that prosegment removal activates lectin antibacterial activity, we generated recombinant forms of RegIIIgamma and HIP/PAP that lacked their N-terminal prosegments. 10 mum of recombinant mature RegIIIgamma (rRegIIIgamma) decreased L. monocytogenes viability by over 99%, as compared with a 12% decrease for rpro-RegIIIgamma (Fig. 2D). Similarly, 10 mum of recombinant mature HIP/PAP (rHIP/PAP) killed >99.9% of organisms, as compared with 56% for rpro-HIP/PAP (Fig. 2E). Addition of the HIP/PAP N-terminal prosegment in trans did not reduce the antibacterial activity of rHIP/PAP (Fig. 2F), indicating that the prosegment is inhibitory only when covalently attached (in cis). Peptidoglycan pull-down assays established that prosegment removal did not diminish the ability of either the human or mouse protein to bind peptidoglycan (Fig. 3). Collectively, these data establish that the RegIII lectin N-terminal prosegment inhibits antibacterial activity in cis, but does not affect peptidoglycan binding.
###end p 29
###begin p 30
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 77 9 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Peptidoglycan binding activity is not altered by prosegment removal.</bold>
###xml 266 267 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 286 287 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 9 325 9 319 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><bold>Peptidoglycan binding activity is not altered by prosegment removal.</bold> Recombinant unprocessed and processed RegIII&#947; and HIP/PAP were compared in peptidoglycan pull-down assays. 20 &#956;g of protein was added to 50 &#956;g of peptidoglycan and pelleted. Pellet (<italic>P</italic>) and supernatant (<italic>S</italic>) fractions were analyzed by SDS-PAGE.</p>
###xml 9 325 9 319 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31"><bold>Peptidoglycan binding activity is not altered by prosegment removal.</bold> Recombinant unprocessed and processed RegIII&#947; and HIP/PAP were compared in peptidoglycan pull-down assays. 20 &#956;g of protein was added to 50 &#956;g of peptidoglycan and pelleted. Pellet (<italic>P</italic>) and supernatant (<italic>S</italic>) fractions were analyzed by SDS-PAGE.</p></caption>
###xml 325 325 319 319 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420003"/>
###xml 0 325 0 319 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="31"><bold>Peptidoglycan binding activity is not altered by prosegment removal.</bold> Recombinant unprocessed and processed RegIII&#947; and HIP/PAP were compared in peptidoglycan pull-down assays. 20 &#956;g of protein was added to 50 &#956;g of peptidoglycan and pelleted. Pellet (<italic>P</italic>) and supernatant (<italic>S</italic>) fractions were analyzed by SDS-PAGE.</p></caption><graphic xlink:href="zbc0110967420003"/></fig>
FIGURE 3.Peptidoglycan binding activity is not altered by prosegment removal. Recombinant unprocessed and processed RegIIIgamma and HIP/PAP were compared in peptidoglycan pull-down assays. 20 mug of protein was added to 50 mug of peptidoglycan and pelleted. Pellet (P) and supernatant (S) fractions were analyzed by SDS-PAGE.
###end p 30
###begin p 31
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Peptidoglycan binding activity is not altered by prosegment removal.</bold>
###xml 257 258 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 277 278 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Peptidoglycan binding activity is not altered by prosegment removal. Recombinant unprocessed and processed RegIIIgamma and HIP/PAP were compared in peptidoglycan pull-down assays. 20 mug of protein was added to 50 mug of peptidoglycan and pelleted. Pellet (P) and supernatant (S) fractions were analyzed by SDS-PAGE.
###end p 31
###begin p 32
###xml 143 144 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 804 805 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 810 811 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 796 811 776 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>A</italic> and <italic>B</italic></xref>
We previously reported bactericidal activity for recombinant RegIIIgamma and HIP/PAP that were expressed with an intact N-terminal prosegment (5). To determine why we were able to detect antibacterial activity in these protein preparations, we investigated the fate of the pro-HIP/PAP N terminus during storage. We noted that the rpro-HIP/PAP is labile and the N terminus is progressively removed over time during storage at 4 degreesC (supplemental Fig. S1). The presence of small amounts of mature HIP/PAP is thus likely to account for the antibacterial activity of protein preparations derived from recombinant prosegment-containing lectins. This may also explain why we detect modest antibacterial activity in rpro-RegIIIgamma and rpro-HIP/PAP following mock digestion for 2 h at 37degreesC (Fig. 2, A and B).
###end p 32
###begin p 33
###xml 0 75 0 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-terminal Acidic Residues Are Essential for Prosegment Inhibitory Activity</italic>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 325 332 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 446 448 446 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">27</sup>
###xml 453 455 453 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">28</sup>
###xml 464 466 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 592 599 592 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 637 638 636 637 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 648 664 647 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 841 842 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 835 842 834 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1012 1028 1011 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 1039 1040 1037 1038 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1062 1063 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1056 1063 1054 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 286 291 <span type="species:ncbi:10090">mouse</span>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 648 664 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 1012 1028 <span type="species:ncbi:1639">L. monocytogenes</span>
N-terminal Acidic Residues Are Essential for Prosegment Inhibitory Activity-We next sought to gain insight into the inhibitory mechanism of the RegIII lectin N-terminal prosegment. We noted the presence of either two or three acidic residues (Glu or Asp) at conserved positions in both mouse and human RegIII family members (Fig. 1B). To evaluate the functional importance of the three acidic residues contained within the HIP/PAP prosegment (Glu27, Glu28, and Glu32), we mutated combinations of these residues to Ala and assessed the mutant rpro-HIP/PAP proteins for antibacterial activity (Fig. 4A). Recombinant pro-HIP/PAP-E32A (10 mum) reduced L. monocytogenes viability by 30%, while rpro-HIP/PAP-EE/AA (harboring E27A and E28A mutations) produced a 75% decline in bacterial colony forming units (CFUs) at the same concentration (Fig. 4B). In contrast, mutation of all three acidic residues (rpro-HIP/PAP-EEE/AAA) yielded a prosegment-containing protein that produced a >99.9% reduction in the viability of L. monocytogenes at a 10 mum concentration (Fig. 4B). This demonstrates that multiple N-terminal acidic residues are essential for HIP/PAP prosegment inhibitory function, and suggests that the degree of inhibitory activity is dictated by charge.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 84 9 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">N-terminal acidic resides are essential for prosegment inhibitory activity.</bold>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 318 319 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 373 379 373 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 9 380 9 380 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>N-terminal acidic resides are essential for prosegment inhibitory activity.</bold><italic>A</italic>, primary structure of the pro-HIP/PAP N terminus showing the positions of engineered mutations. <italic>B</italic>, comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring mutations in N-terminal glutamic acid (<italic>E</italic>) residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p>
###xml 9 380 9 380 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>N-terminal acidic resides are essential for prosegment inhibitory activity.</bold><italic>A</italic>, primary structure of the pro-HIP/PAP N terminus showing the positions of engineered mutations. <italic>B</italic>, comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring mutations in N-terminal glutamic acid (<italic>E</italic>) residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p></caption>
###xml 380 380 380 380 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420004"/>
###xml 0 380 0 380 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="35"><bold>N-terminal acidic resides are essential for prosegment inhibitory activity.</bold><italic>A</italic>, primary structure of the pro-HIP/PAP N terminus showing the positions of engineered mutations. <italic>B</italic>, comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring mutations in N-terminal glutamic acid (<italic>E</italic>) residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p></caption><graphic xlink:href="zbc0110967420004"/></fig>
FIGURE 4.N-terminal acidic resides are essential for prosegment inhibitory activity.A, primary structure of the pro-HIP/PAP N terminus showing the positions of engineered mutations. B, comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring mutations in N-terminal glutamic acid (E) residues. Antibacterial assays were performed as in Fig. 2.
###end p 34
###begin p 35
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">N-terminal acidic resides are essential for prosegment inhibitory activity.</bold>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 309 310 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 364 370 364 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
N-terminal acidic resides are essential for prosegment inhibitory activity.A, primary structure of the pro-HIP/PAP N terminus showing the positions of engineered mutations. B, comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring mutations in N-terminal glutamic acid (E) residues. Antibacterial assays were performed as in Fig. 2.
###end p 35
###begin p 36
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 44 9 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The HIP/PAP N terminus is flexible.</bold>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 188 199 188 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</italic>
###xml 253 256 253 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 323 324 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 401 402 401 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 404 405 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 445 447 445 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 451 453 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 485 500 485 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed red line</italic>
###xml 9 501 9 501 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><bold>The HIP/PAP N terminus is flexible.</bold><italic>A</italic>, ribbon diagram of the pro-HIP/PAP crystal structure (RCSB accession: 1UV0) (<xref ref-type="bibr" rid="ref15">15</xref>). The disordered N-terminal 10 amino acids are indicated by a <italic>dotted line</italic>, and the locations of the N-terminal disulfide bond (<italic>red</italic>) and the trypsin cleavage site are indicated. <italic>B</italic>, experimental <sup>15</sup>NR<sub>1</sub> and R<sub>2</sub> relaxation rates were determined for pro-HIP/PAP, and a plot of the R<sub>1</sub>/R<sub>2</sub> ratio is shown. The location of the Arg<sup>37</sup>&#8211;Ile<sup>38</sup> trypsin site is indicated by a <italic>dashed red line</italic>.</p>
###xml 9 501 9 501 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><bold>The HIP/PAP N terminus is flexible.</bold><italic>A</italic>, ribbon diagram of the pro-HIP/PAP crystal structure (RCSB accession: 1UV0) (<xref ref-type="bibr" rid="ref15">15</xref>). The disordered N-terminal 10 amino acids are indicated by a <italic>dotted line</italic>, and the locations of the N-terminal disulfide bond (<italic>red</italic>) and the trypsin cleavage site are indicated. <italic>B</italic>, experimental <sup>15</sup>NR<sub>1</sub> and R<sub>2</sub> relaxation rates were determined for pro-HIP/PAP, and a plot of the R<sub>1</sub>/R<sub>2</sub> ratio is shown. The location of the Arg<sup>37</sup>&#8211;Ile<sup>38</sup> trypsin site is indicated by a <italic>dashed red line</italic>.</p></caption>
###xml 501 501 501 501 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420005"/>
###xml 0 501 0 501 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="37"><bold>The HIP/PAP N terminus is flexible.</bold><italic>A</italic>, ribbon diagram of the pro-HIP/PAP crystal structure (RCSB accession: 1UV0) (<xref ref-type="bibr" rid="ref15">15</xref>). The disordered N-terminal 10 amino acids are indicated by a <italic>dotted line</italic>, and the locations of the N-terminal disulfide bond (<italic>red</italic>) and the trypsin cleavage site are indicated. <italic>B</italic>, experimental <sup>15</sup>NR<sub>1</sub> and R<sub>2</sub> relaxation rates were determined for pro-HIP/PAP, and a plot of the R<sub>1</sub>/R<sub>2</sub> ratio is shown. The location of the Arg<sup>37</sup>&#8211;Ile<sup>38</sup> trypsin site is indicated by a <italic>dashed red line</italic>.</p></caption><graphic xlink:href="zbc0110967420005"/></fig>
FIGURE 5.The HIP/PAP N terminus is flexible.A, ribbon diagram of the pro-HIP/PAP crystal structure (RCSB accession: 1UV0) (15). The disordered N-terminal 10 amino acids are indicated by a dotted line, and the locations of the N-terminal disulfide bond (red) and the trypsin cleavage site are indicated. B, experimental 15NR1 and R2 relaxation rates were determined for pro-HIP/PAP, and a plot of the R1/R2 ratio is shown. The location of the Arg37-Ile38 trypsin site is indicated by a dashed red line.
###end p 36
###begin p 37
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The HIP/PAP N terminus is flexible.</bold>
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 179 190 179 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</italic>
###xml 244 247 244 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 310 312 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 314 315 314 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 321 322 321 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 392 393 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 395 396 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 436 438 436 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 442 444 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 476 491 476 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed red line</italic>
The HIP/PAP N terminus is flexible.A, ribbon diagram of the pro-HIP/PAP crystal structure (RCSB accession: 1UV0) (15). The disordered N-terminal 10 amino acids are indicated by a dotted line, and the locations of the N-terminal disulfide bond (red) and the trypsin cleavage site are indicated. B, experimental 15NR1 and R2 relaxation rates were determined for pro-HIP/PAP, and a plot of the R1/R2 ratio is shown. The location of the Arg37-Ile38 trypsin site is indicated by a dashed red line.
###end p 37
###begin p 38
###xml 0 57 0 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Structural Analysis of the HIP/PAP-Prosegment Interaction</italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 295 302 295 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 638 640 638 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 642 644 642 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 850 852 850 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 1048 1049 1047 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1079 1080 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1124 1125 1123 1124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1127 1128 1126 1127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1167 1168 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1161 1168 1160 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 1312 1314 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1320 1321 1319 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1323 1324 1322 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
Structural Analysis of the HIP/PAP-Prosegment Interaction-Although the crystal structure of pro-HIP/PAP has been determined (15), it offered limited information about the HIP/PAP-prosegment interaction. In particular, N-terminal residues 27-35 are disordered and thus absent from the structure (Fig. 5A) and residues 36-41 appear to be involved in crystal packing interactions, raising questions about the observed structure of this essential region of the protein. We therefore used nuclear magnetic resonance (NMR) spectroscopy to structurally characterize the interaction between HIP/PAP and its N-terminal prosegment. Using uniformly 15N,13C-labeled pro-HIP/PAP and standard triple resonance methods (16) we assigned the chemical shifts of 98% of the backbone resonances. We first analyzed the conformational dynamics of pro-HIP/PAP by measuring 15N relaxation rates, which are influenced by fast (ps-ns) and slow (mus-ms) motions of backbone amides throughout a protein. In particular, we measured rate constants for spin-lattice relaxation (R1), and spin-spin relaxation (R2), finding that the ratio of these values (R1/R2) was highest in residues 27-34 (Fig. 5B). This indicates a high degree of backbone conformational mobility at the N terminus. Furthermore, TALOS analyses of backbone chemical shifts (17) and 1H-1H NOEs indicated that the prosegment adopts an extended structure. Together, these data suggest that the prosegment is flexible and transiently interacts with the rest of the protein.
###end p 38
###begin p 39
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 98 9 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.</bold>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 243 251 243 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow. B</italic>
###xml 495 501 495 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 533 535 533 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">39</sup>
###xml 540 542 540 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">42</sup>
###xml 547 549 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 821 827 821 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 9 828 9 828 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><bold>HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.</bold><italic>A</italic>, orientation of Arg and Lys side chains near the HIP/PAP N-terminal trypsin site. The location of the trypsin cleavage site is indicated by an <italic>arrow. B</italic>, mutations of basic HIP/PAP residues yield active rpro-HIP/PAP. Comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring the indicated mutations in basic residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. <italic>C</italic>, HIP/PAP basic residues (Arg<sup>39</sup>, Lys<sup>42</sup>, Lys<sup>45</sup>) are dispensable for antibacterial activity. Limited trypsin proteolysis was performed on rpro-HIP/PAP-RKK/AAA. SDS-PAGE analysis of the undigested and digested proteins is depicted. Digested and undigested proteins were analyzed for bactericidal activity as outlined in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p>
###xml 9 828 9 828 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><bold>HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.</bold><italic>A</italic>, orientation of Arg and Lys side chains near the HIP/PAP N-terminal trypsin site. The location of the trypsin cleavage site is indicated by an <italic>arrow. B</italic>, mutations of basic HIP/PAP residues yield active rpro-HIP/PAP. Comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring the indicated mutations in basic residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. <italic>C</italic>, HIP/PAP basic residues (Arg<sup>39</sup>, Lys<sup>42</sup>, Lys<sup>45</sup>) are dispensable for antibacterial activity. Limited trypsin proteolysis was performed on rpro-HIP/PAP-RKK/AAA. SDS-PAGE analysis of the undigested and digested proteins is depicted. Digested and undigested proteins were analyzed for bactericidal activity as outlined in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p></caption>
###xml 828 828 828 828 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420006"/>
###xml 0 828 0 828 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="40"><bold>HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.</bold><italic>A</italic>, orientation of Arg and Lys side chains near the HIP/PAP N-terminal trypsin site. The location of the trypsin cleavage site is indicated by an <italic>arrow. B</italic>, mutations of basic HIP/PAP residues yield active rpro-HIP/PAP. Comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring the indicated mutations in basic residues. Antibacterial assays were performed as in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. <italic>C</italic>, HIP/PAP basic residues (Arg<sup>39</sup>, Lys<sup>42</sup>, Lys<sup>45</sup>) are dispensable for antibacterial activity. Limited trypsin proteolysis was performed on rpro-HIP/PAP-RKK/AAA. SDS-PAGE analysis of the undigested and digested proteins is depicted. Digested and undigested proteins were analyzed for bactericidal activity as outlined in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.</p></caption><graphic xlink:href="zbc0110967420006"/></fig>
FIGURE 6.HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.A, orientation of Arg and Lys side chains near the HIP/PAP N-terminal trypsin site. The location of the trypsin cleavage site is indicated by an arrow. B, mutations of basic HIP/PAP residues yield active rpro-HIP/PAP. Comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring the indicated mutations in basic residues. Antibacterial assays were performed as in Fig. 2. C, HIP/PAP basic residues (Arg39, Lys42, Lys45) are dispensable for antibacterial activity. Limited trypsin proteolysis was performed on rpro-HIP/PAP-RKK/AAA. SDS-PAGE analysis of the undigested and digested proteins is depicted. Digested and undigested proteins were analyzed for bactericidal activity as outlined in Fig. 2.
###end p 39
###begin p 40
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.</bold>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 234 242 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow. B</italic>
###xml 486 492 486 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 524 526 524 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">39</sup>
###xml 531 533 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">42</sup>
###xml 538 540 538 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 812 818 812 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
HIP/PAP basic residues are essential for prosegment inhibition of antibacterial activity.A, orientation of Arg and Lys side chains near the HIP/PAP N-terminal trypsin site. The location of the trypsin cleavage site is indicated by an arrow. B, mutations of basic HIP/PAP residues yield active rpro-HIP/PAP. Comparison of antibacterial activity among rpro-HIP/PAP, rHIP/PAP, and rpro-HIP/PAP harboring the indicated mutations in basic residues. Antibacterial assays were performed as in Fig. 2. C, HIP/PAP basic residues (Arg39, Lys42, Lys45) are dispensable for antibacterial activity. Limited trypsin proteolysis was performed on rpro-HIP/PAP-RKK/AAA. SDS-PAGE analysis of the undigested and digested proteins is depicted. Digested and undigested proteins were analyzed for bactericidal activity as outlined in Fig. 2.
###end p 40
###begin p 41
###xml 0 88 0 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIP/PAP Basic Residues Are Essential for Prosegment Inhibition of Antibacterial Activity</italic>
###xml 734 736 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">39</sup>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">42</sup>
###xml 748 750 748 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 796 798 796 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 802 804 802 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 827 828 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">1<italic>B</italic></xref>
###xml 834 835 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">6<italic>A</italic></xref>
###xml 1142 1158 1142 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 1176 1177 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1170 1177 1170 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 1320 1321 1320 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1314 1321 1314 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 1142 1158 <span type="species:ncbi:1639">L. monocytogenes</span>
HIP/PAP Basic Residues Are Essential for Prosegment Inhibition of Antibacterial Activity-These findings suggested that the HIP/PAP N-terminal peptide may inhibit antibacterial activity through dynamic interactions with other residues in the HIP/PAP core protein. Given that acidic amino acids in the N terminus are essential for prosegment inhibitory activity, we hypothesized that interactions with nearby HIP/PAP basic residues may be required for repression of antibacterial activity. Because the prosegment is only 11 amino acids in length, we reasoned that it was likely to be constrained to local interactions with amino acids near the trypsin site. Examination of the HIP/PAP primary sequence revealed three basic residues (Arg39, Lys42, Lys45) positioned immediately C-terminal to the Arg37-Ile38 cleavage site (Figs. 1B and 6A). While introduction of a single mutation (R39A) was insufficient to activate antimicrobial activity in rpro-HIP/PAP, mutation of all three basic amino acids to alanine (rpro-HIP/PAP-RKK/AAA) yielded a prosegment-containing variant that exhibited potent antibacterial activity, producing a >99% decline in L. monocytogenes viability (Fig. 6B). Critically, the presence of these mutations had no effect on the antimicrobial activity of the mature protein lacking the prosegment (Fig. 6C). These data demonstrate that basic HIP/PAP residues, positioned C-terminal to the trypsin site, are essential for prosegment inhibitory activity but are dispensable for antibacterial function.
###end p 41
###begin p 42
###xml 0 54 0 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Structural Effects of Activating Pro-HIP/PAP Mutations</italic>
###xml 539 541 539 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 819 821 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 829 830 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 823 830 815 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>A</italic></xref>
###xml 1185 1187 1177 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 1189 1190 1181 1182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1596 1597 1587 1588 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Structural Effects of Activating Pro-HIP/PAP Mutations-Overall, these results suggested a model in which the prosegment maintains HIP/PAP in an inactive state through transient interactions between acidic N-terminal residues and basic residues positioned C-terminal to the trypsin site. Mutation of these charged residues derepresses HIP/PAP antibacterial activity in the prosegment-containing protein, thus mimicking the derepression that occurs when the peptide is removed by proteolysis. To further examine this interaction we compared 15N/1H heteronuclear single quantum coherence (HSQC) spectra of rpro-HIP/PAP glutamic acid-to-alanine mutants with the wild-type protein (supplemental Fig. S2). We observed significant chemical shift changes (Deltadelta > 0.05 ppm) only in residues N-terminal to and including Ile38 (Fig. 7A). This verified that the gain-of-function phenotype produced by the EEE/AAA and RKK/AAA mutations did not result from gross protein misfolding. Furthermore, the lack of significant chemical shift changes in the main body of the protein argues against prosegment inhibitory activity being related to global changes in the core HIP/PAP structure. Notably, 15N/1H HSQC spectra of HIP/PAP with and without the wild-type prosegment showed no significant chemical shift changes aside from those at the trypsin cleavage site, confirming that proteolysis itself also does not cause a global conformational change (data not shown). Analysis of peak intensity did not reveal evidence of prosegment-modulated dimer or oligomer formation, even at the high concentration (300 mum) used for NMR spectroscopy (data not shown). However, as these spectra were collected in the absence of ligand, the possibility remains that multimer formation may occur in the presence of peptidoglycan ligands.
###end p 42
###begin p 43
###xml 116 118 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 229 231 229 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">36</sup>
###xml 243 245 243 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>B</italic></xref>
###xml 502 509 502 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 970 972 970 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 976 978 976 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 1187 1188 1187 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1181 1188 1181 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7<italic>B</italic></xref>
###xml 1215 1217 1215 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 1219 1220 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1285 1287 1285 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1291 1293 1291 1293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 1602 1608 1602 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
We noted a striking co-linear pattern of change in key N-terminal backbone amide chemical shifts when comparing the 15N/1H HSQC spectra of rpro-HIP/PAP and single, double or triple glutamic acid-to-alanine mutants. Peaks from Ser35, Ala36, Arg37, and Ile38 shifted in the same direction in each of the rpro-HIP/PAP mutants (Fig. 7B), with the triple EEE/AAA mutant exhibiting chemical shift changes that are close to the additive sum of those observed for the single E32A and double E27A/E28A mutants (Table 1) (18). Such a co-linear chemical shift pattern signifies a molecule that is in conformational equilibrium between two states, with intermediate chemical shifts deriving from a population-weighted average of these states (16). Furthermore, the additivity of these chemical shift changes indicates a simple, non-cooperative interaction between the charges on the prosegment and the rest of the HIP/PAP protein. Notably, similar chemical shift changes for the Ser35-Ile38 segment were observed in the activated rpro-HIP/PAP-RKK/AAA mutant, suggesting that the same conformational change is being triggered from the "opposite" side of the putative charge/charge interaction (Fig. 7B). Close inspection of the 15N/1H HSQC spectrum for this mutant shows that peaks for residues Ser35-Ile38 are doubled on this vector, indicative of further conformational exchange occurring on a slow time scale. Collectively, these data support a model in which perturbation of the interaction between HIP/PAP and its prosegment drives a shift in the conformational equilibrium toward a biologically active state (Fig. 8). Our data further suggest that the degree to which the prosegment shifts the HIP/PAP population to the inactive state is simply determined by the number of intramolecular charge-charge interactions rather than any specific ordering of the prosegment against the core HIP/PAP structure.
###end p 43
###begin p 44
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 77 7 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Simple additivity of chemical shift differences in HIP/PAP E/A mutants</bold>
###xml 7 77 7 77 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><bold>Simple additivity of chemical shift differences in HIP/PAP E/A mutants</bold></p>
###xml 7 77 7 77 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45"><bold>Simple additivity of chemical shift differences in HIP/PAP E/A mutants</bold></p></caption>
###xml 77 77 77 77 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 77 80 77 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">S35</bold>
###xml 77 80 77 80 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>S35</bold></th>
###xml 80 83 80 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A36</bold>
###xml 80 83 80 83 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>A36</bold></th>
###xml 83 86 83 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">R37</bold>
###xml 83 86 83 86 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>R37</bold></th>
###xml 86 89 86 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I38</bold>
###xml 86 89 86 89 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>I38</bold></th>
###xml 77 89 77 89 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>S35</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>A36</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>R37</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>I38</bold></th></tr>
###xml 77 89 77 89 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>S35</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>A36</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>R37</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>I38</bold></th></tr></thead>
###xml 89 89 89 89 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ppm</italic>
###xml 89 92 89 92 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ppm</italic>
###xml 92 95 92 95 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td>
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ppm</italic>
###xml 95 98 95 98 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ppm</italic>
###xml 98 101 98 101 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td>
###xml 89 101 89 101 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td></tr>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 101 114 101 114 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> E/A<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E32A) </td>
###xml 114 121 114 121 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.565 </td>
###xml 121 128 121 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.265 </td>
###xml 128 135 128 135 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.543 </td>
###xml 135 142 135 142 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.399 </td>
###xml 101 142 101 142 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> E/A<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.565 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.265 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.543 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.399 </td></tr>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 142 162 142 162 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> EE/AA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A) </td>
###xml 162 169 162 169 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.542 </td>
###xml 169 176 169 176 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.268 </td>
###xml 176 183 176 183 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.318 </td>
###xml 183 190 183 190 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.510 </td>
###xml 142 190 142 190 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> EE/AA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.542 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.268 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.318 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.510 </td></tr>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 190 217 190 217 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> EEE/AAA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A/E32A) </td>
###xml 217 224 217 224 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.017 </td>
###xml 224 231 224 231 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.511 </td>
###xml 231 238 231 238 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.859 </td>
###xml 238 245 238 245 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.872 </td>
###xml 190 245 190 245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> EEE/AAA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A/E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.017 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.511 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.859 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.872 </td></tr>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref>
###xml 245 280 245 280 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Calculated EEE/AAA<xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref> (E/A + EE/AA) </td>
###xml 280 287 280 287 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.107 </td>
###xml 287 294 287 294 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.533 </td>
###xml 294 301 294 301 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.861 </td>
###xml 301 308 301 308 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.909 </td>
###xml 245 308 245 308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Calculated EEE/AAA<xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref> (E/A + EE/AA) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.107 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.533 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.861 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.909 </td></tr>
###xml 89 308 89 308 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E/A<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.565 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.265 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.543 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.399 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EE/AA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.542 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.268 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.318 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.510 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EEE/AAA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A/E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.017 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.511 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.859 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.872 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Calculated EEE/AAA<xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref> (E/A + EE/AA) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.107 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.533 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.861 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.909 </td></tr></tbody>
###xml 77 308 77 308 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>S35</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>A36</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>R37</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>I38</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E/A<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.565 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.265 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.543 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.399 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EE/AA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.542 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.268 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.318 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.510 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EEE/AAA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A/E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.017 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.511 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.859 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.872 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Calculated EEE/AAA<xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref> (E/A + EE/AA) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.107 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.533 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.861 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.909 </td></tr></tbody></table>
###xml 308 309 308 309 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 347 350 339 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TOT</sub>
###xml 406 409 390 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TOT</sub>
###xml 423 424 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 426 427 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 447 449 413 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 451 452 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 453 456 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1/2</sup>
###xml 607 609 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 309 611 309 575 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Chemical shift differences (&#916;&#948;<sub>TOT</sub>) were obtained using the following equation: &#916;&#948;<sub>TOT</sub> = [&#916;&#948;<sup>1</sup>H)<sup>2</sup> + (&#967; &#215; &#916;&#948;<sup>15</sup>N)<sup>2</sup>]<sup>1/2</sup> (normalized for proton with the scale factor &#967; = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
###xml 308 611 308 575 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn1"><label>a</label><p textid="46">Chemical shift differences (&#916;&#948;<sub>TOT</sub>) were obtained using the following equation: &#916;&#948;<sub>TOT</sub> = [&#916;&#948;<sup>1</sup>H)<sup>2</sup> + (&#967; &#215; &#916;&#948;<sup>15</sup>N)<sup>2</sup>]<sup>1/2</sup> (normalized for proton with the scale factor &#967; = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (<xref ref-type="bibr" rid="ref14">14</xref>).</p></fn>
###xml 611 612 575 576 <label xmlns:xlink="http://www.w3.org/1999/xlink">b</label>
###xml 612 717 576 657 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Calculated chemical shift differences were determined by &#916;&#948;TOT = &#916;&#948;E/A + &#916;&#948;EE/AA.</p>
###xml 611 717 575 657 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn2"><label>b</label><p textid="47">Calculated chemical shift differences were determined by &#916;&#948;TOT = &#916;&#948;E/A + &#916;&#948;EE/AA.</p></fn>
###xml 308 717 308 657 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn1"><label>a</label><p textid="46">Chemical shift differences (&#916;&#948;<sub>TOT</sub>) were obtained using the following equation: &#916;&#948;<sub>TOT</sub> = [&#916;&#948;<sup>1</sup>H)<sup>2</sup> + (&#967; &#215; &#916;&#948;<sup>15</sup>N)<sup>2</sup>]<sup>1/2</sup> (normalized for proton with the scale factor &#967; = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (<xref ref-type="bibr" rid="ref14">14</xref>).</p></fn><fn id="tblfn2"><label>b</label><p textid="47">Calculated chemical shift differences were determined by &#916;&#948;TOT = &#916;&#948;E/A + &#916;&#948;EE/AA.</p></fn></table-wrap-foot>
###xml 0 717 0 657 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="45"><bold>Simple additivity of chemical shift differences in HIP/PAP E/A mutants</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>S35</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>A36</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>R37</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>I38</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>ppm</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E/A<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.565 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.265 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.543 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.399 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EE/AA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.542 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.268 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.318 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.510 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> EEE/AAA<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> (E27A/E28A/E32A) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.017 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.511 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.859 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.872 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Calculated EEE/AAA<xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref> (E/A + EE/AA) </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.107 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.533 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.861 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.909 </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p textid="46">Chemical shift differences (&#916;&#948;<sub>TOT</sub>) were obtained using the following equation: &#916;&#948;<sub>TOT</sub> = [&#916;&#948;<sup>1</sup>H)<sup>2</sup> + (&#967; &#215; &#916;&#948;<sup>15</sup>N)<sup>2</sup>]<sup>1/2</sup> (normalized for proton with the scale factor &#967; = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (<xref ref-type="bibr" rid="ref14">14</xref>).</p></fn><fn id="tblfn2"><label>b</label><p textid="47">Calculated chemical shift differences were determined by &#916;&#948;TOT = &#916;&#948;E/A + &#916;&#948;EE/AA.</p></fn></table-wrap-foot></table-wrap>
TABLE 1Simple additivity of chemical shift differences in HIP/PAP E/A mutantsS35A36R37I38ppmppmppmppm E/Aa (E32A)  0.565  0.265  0.543  0.399  EE/AAa (E27A/E28A)  0.542  0.268  0.318  0.510  EEE/AAAa (E27A/E28A/E32A)  1.017  0.511  0.859  0.872  Calculated EEE/AAAb (E/A + EE/AA)  1.107  0.533  0.861  0.909 aChemical shift differences (DeltadeltaTOT) were obtained using the following equation: DeltadeltaTOT = [Deltadelta1H)2 + (chi x Deltadelta15N)2]1/2 (normalized for proton with the scale factor chi = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (14).bCalculated chemical shift differences were determined by DeltadeltaTOT = DeltadeltaE/A + DeltadeltaEE/AA.
###end p 44
###begin p 45
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Simple additivity of chemical shift differences in HIP/PAP E/A mutants</bold>
Simple additivity of chemical shift differences in HIP/PAP E/A mutants
###end p 45
###begin p 46
###xml 38 41 30 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TOT</sub>
###xml 97 100 81 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">TOT</sub>
###xml 114 115 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 117 118 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 138 140 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 142 143 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 144 147 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1/2</sup>
###xml 298 300 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
Chemical shift differences (DeltadeltaTOT) were obtained using the following equation: DeltadeltaTOT = [Deltadelta1H)2 + (chi x Deltadelta15N)2]1/2 (normalized for proton with the scale factor chi = 0.17, established from estimates of atom-specific chemical shift ranges in a protein environment) (14).
###end p 46
###begin p 47
Calculated chemical shift differences were determined by DeltadeltaTOT = DeltadeltaE/A + DeltadeltaEE/AA.
###end p 47
###begin p 48
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 9 64 9 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural effects of activating pro-HIP/PAP mutations.</bold>
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 280 288 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red line</italic>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 346 348 346 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 350 351 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 369 371 369 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 541 543 541 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 547 549 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 9 686 9 686 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49"><bold>Structural effects of activating pro-HIP/PAP mutations.</bold><italic>A</italic>, chemical shift changes in the <sup>15</sup>N/<sup>1</sup>H HSQC spectra of rpro-HIP/PAP and the activated mutant rpro-HIP/PAP-EEE/AAA are plotted as a function of residue number. Chemical shift changes &gt;0.05 ppm are indicated with the <italic>red line</italic>. The trypsin cleavage site is indicated. <italic>B</italic>, superimposed <sup>15</sup>N/<sup>1</sup>H HSQC spectra of <sup>15</sup>N-labeled rpro-HIP/PAP and activating rpro-HIP/PAP mutations reveal colinear chemical shift perturbations among four residues surrounding the trypsin cleavage site at Arg<sup>37</sup>/Ser<sup>38</sup>. <italic>Arrows</italic> indicate the direction of larger chemical shift changes from wild-type and progression toward enhanced HIP/PAP killing activity.</p>
###xml 9 686 9 686 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49"><bold>Structural effects of activating pro-HIP/PAP mutations.</bold><italic>A</italic>, chemical shift changes in the <sup>15</sup>N/<sup>1</sup>H HSQC spectra of rpro-HIP/PAP and the activated mutant rpro-HIP/PAP-EEE/AAA are plotted as a function of residue number. Chemical shift changes &gt;0.05 ppm are indicated with the <italic>red line</italic>. The trypsin cleavage site is indicated. <italic>B</italic>, superimposed <sup>15</sup>N/<sup>1</sup>H HSQC spectra of <sup>15</sup>N-labeled rpro-HIP/PAP and activating rpro-HIP/PAP mutations reveal colinear chemical shift perturbations among four residues surrounding the trypsin cleavage site at Arg<sup>37</sup>/Ser<sup>38</sup>. <italic>Arrows</italic> indicate the direction of larger chemical shift changes from wild-type and progression toward enhanced HIP/PAP killing activity.</p></caption>
###xml 686 686 686 686 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420007"/>
###xml 0 686 0 686 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="49"><bold>Structural effects of activating pro-HIP/PAP mutations.</bold><italic>A</italic>, chemical shift changes in the <sup>15</sup>N/<sup>1</sup>H HSQC spectra of rpro-HIP/PAP and the activated mutant rpro-HIP/PAP-EEE/AAA are plotted as a function of residue number. Chemical shift changes &gt;0.05 ppm are indicated with the <italic>red line</italic>. The trypsin cleavage site is indicated. <italic>B</italic>, superimposed <sup>15</sup>N/<sup>1</sup>H HSQC spectra of <sup>15</sup>N-labeled rpro-HIP/PAP and activating rpro-HIP/PAP mutations reveal colinear chemical shift perturbations among four residues surrounding the trypsin cleavage site at Arg<sup>37</sup>/Ser<sup>38</sup>. <italic>Arrows</italic> indicate the direction of larger chemical shift changes from wild-type and progression toward enhanced HIP/PAP killing activity.</p></caption><graphic xlink:href="zbc0110967420007"/></fig>
FIGURE 7.Structural effects of activating pro-HIP/PAP mutations.A, chemical shift changes in the 15N/1H HSQC spectra of rpro-HIP/PAP and the activated mutant rpro-HIP/PAP-EEE/AAA are plotted as a function of residue number. Chemical shift changes >0.05 ppm are indicated with the red line. The trypsin cleavage site is indicated. B, superimposed 15N/1H HSQC spectra of 15N-labeled rpro-HIP/PAP and activating rpro-HIP/PAP mutations reveal colinear chemical shift perturbations among four residues surrounding the trypsin cleavage site at Arg37/Ser38. Arrows indicate the direction of larger chemical shift changes from wild-type and progression toward enhanced HIP/PAP killing activity.
###end p 48
###begin p 49
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural effects of activating pro-HIP/PAP mutations.</bold>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red line</italic>
###xml 321 322 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 337 339 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 360 362 360 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 532 534 532 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 538 540 538 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">38</sup>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
Structural effects of activating pro-HIP/PAP mutations.A, chemical shift changes in the 15N/1H HSQC spectra of rpro-HIP/PAP and the activated mutant rpro-HIP/PAP-EEE/AAA are plotted as a function of residue number. Chemical shift changes >0.05 ppm are indicated with the red line. The trypsin cleavage site is indicated. B, superimposed 15N/1H HSQC spectra of 15N-labeled rpro-HIP/PAP and activating rpro-HIP/PAP mutations reveal colinear chemical shift perturbations among four residues surrounding the trypsin cleavage site at Arg37/Ser38. Arrows indicate the direction of larger chemical shift changes from wild-type and progression toward enhanced HIP/PAP killing activity.
###end p 49
###begin title 50
DISCUSSION
###end title 50
###begin p 51
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 402 409 402 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 813 819 813 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
The RegIII lectins constitute a vital component of the intestinal epithelial antibacterial arsenal which protect the host against pathogens (19) and maintain homeostasis with symbiotic bacteria (5). However, little is known about how RegIII antibacterial activity is regulated. In this report we show that RegIII lectins are subject to repression by an inhibitory N-terminal prosegment that is removed in vivo by trypsin. This represents a novel regulatory mechanism governing C-type lectin biological activity. The inhibitory activity of the N-terminal segment depends on charge-charge interactions with the main body of the protein. Derepression of antibacterial activity occurs when these interactions are perturbed, either through proteolytic removal of the prosegment or by mutation of the charged residues (Fig. 8).
###end p 51
###begin p 52
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 8.</label>
###xml 9 74 9 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model of HIP/PAP prosegment inhibition of antibacterial activity.</bold>
###xml 101 112 101 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed line</italic>
###xml 175 184 175 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inhibited</italic>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">active</italic>
###xml 824 838 812 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shown in white</italic>
###xml 9 954 9 942 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53"><bold>Model of HIP/PAP prosegment inhibition of antibacterial activity.</bold> The HIP/PAP hinge region (<italic>dashed line</italic>) undergoes a two-state conformational shift between a closed (<italic>inhibited</italic>) and an open (<italic>active</italic>) form. Maintenance of the closed, inactive state depends on transient interactions between negatively charged prosegment residues and positively charged residues on the HIP/PAP core protein. Inhibition is relieved either by cleavage at a conserved trypsin site in the hinge region, or by mutation of either charged region, leading to a &#8764;1000-fold increase in antibacterial activity. Note that the hinge region in the activating mutants is in a constitutively open form, as demonstrated by NMR. We propose that disruption of prosegment-core protein interactions alleviates inhibition by unmasking a region (<italic>shown in white</italic>) necessary for bacterial cell surface damage or for multimerization that may be required for bactericidal activity.</p>
###xml 9 954 9 942 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53"><bold>Model of HIP/PAP prosegment inhibition of antibacterial activity.</bold> The HIP/PAP hinge region (<italic>dashed line</italic>) undergoes a two-state conformational shift between a closed (<italic>inhibited</italic>) and an open (<italic>active</italic>) form. Maintenance of the closed, inactive state depends on transient interactions between negatively charged prosegment residues and positively charged residues on the HIP/PAP core protein. Inhibition is relieved either by cleavage at a conserved trypsin site in the hinge region, or by mutation of either charged region, leading to a &#8764;1000-fold increase in antibacterial activity. Note that the hinge region in the activating mutants is in a constitutively open form, as demonstrated by NMR. We propose that disruption of prosegment-core protein interactions alleviates inhibition by unmasking a region (<italic>shown in white</italic>) necessary for bacterial cell surface damage or for multimerization that may be required for bactericidal activity.</p></caption>
###xml 954 954 942 942 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0110967420008"/>
###xml 0 954 0 942 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig8"><label>FIGURE 8.</label><caption><p textid="53"><bold>Model of HIP/PAP prosegment inhibition of antibacterial activity.</bold> The HIP/PAP hinge region (<italic>dashed line</italic>) undergoes a two-state conformational shift between a closed (<italic>inhibited</italic>) and an open (<italic>active</italic>) form. Maintenance of the closed, inactive state depends on transient interactions between negatively charged prosegment residues and positively charged residues on the HIP/PAP core protein. Inhibition is relieved either by cleavage at a conserved trypsin site in the hinge region, or by mutation of either charged region, leading to a &#8764;1000-fold increase in antibacterial activity. Note that the hinge region in the activating mutants is in a constitutively open form, as demonstrated by NMR. We propose that disruption of prosegment-core protein interactions alleviates inhibition by unmasking a region (<italic>shown in white</italic>) necessary for bacterial cell surface damage or for multimerization that may be required for bactericidal activity.</p></caption><graphic xlink:href="zbc0110967420008"/></fig>
FIGURE 8.Model of HIP/PAP prosegment inhibition of antibacterial activity. The HIP/PAP hinge region (dashed line) undergoes a two-state conformational shift between a closed (inhibited) and an open (active) form. Maintenance of the closed, inactive state depends on transient interactions between negatively charged prosegment residues and positively charged residues on the HIP/PAP core protein. Inhibition is relieved either by cleavage at a conserved trypsin site in the hinge region, or by mutation of either charged region, leading to a approximately1000-fold increase in antibacterial activity. Note that the hinge region in the activating mutants is in a constitutively open form, as demonstrated by NMR. We propose that disruption of prosegment-core protein interactions alleviates inhibition by unmasking a region (shown in white) necessary for bacterial cell surface damage or for multimerization that may be required for bactericidal activity.
###end p 52
###begin p 53
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model of HIP/PAP prosegment inhibition of antibacterial activity.</bold>
###xml 92 103 92 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dashed line</italic>
###xml 166 175 166 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inhibited</italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">active</italic>
###xml 815 829 803 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shown in white</italic>
Model of HIP/PAP prosegment inhibition of antibacterial activity. The HIP/PAP hinge region (dashed line) undergoes a two-state conformational shift between a closed (inhibited) and an open (active) form. Maintenance of the closed, inactive state depends on transient interactions between negatively charged prosegment residues and positively charged residues on the HIP/PAP core protein. Inhibition is relieved either by cleavage at a conserved trypsin site in the hinge region, or by mutation of either charged region, leading to a approximately1000-fold increase in antibacterial activity. Note that the hinge region in the activating mutants is in a constitutively open form, as demonstrated by NMR. We propose that disruption of prosegment-core protein interactions alleviates inhibition by unmasking a region (shown in white) necessary for bacterial cell surface damage or for multimerization that may be required for bactericidal activity.
###end p 53
###begin p 54
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 455 460 <span type="species:ncbi:9606">human</span>
This regulatory mechanism may have evolved to give the host control over the timing and location of the expression of RegIII antibacterial activity. As RegIII lectin antibacterial activity involves damage to microbial cell surfaces (5), it is possible that these proteins could also damage host cell membranes. This would suggest a need to maintain RegIII lectins in an inactive state prior to their luminal release. Two trypsin isozymes are expressed in human gut epithelial cells and are stored as inactive zymogens that are activated by proteolysis in the intestinal lumen (9). It thus seems likely that trypsin-mediated activation of RegIII proteins occurs only after they are secreted. Given the fact that we were able to detect processed RegIIIgamma and HIP/PAP in small intestinal tissue extracts, we cannot completely rule out the possibility of some intracellular cleavage. However, it is likely that this reflects extracellular processing of proteins that are trapped in the mucus layer that overlies the intestinal epithelium. Thus, we propose that this regulatory mechanism evolved to ensure that lectin bactericidal activity is inhibited during intracellular storage, and activated upon secretion into the gut lumen.
###end p 54
###begin p 55
###xml 201 202 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 204 205 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 307 308 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 403 404 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 311 316 <span type="species:ncbi:10090">mouse</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 526 532 <span type="species:ncbi:9606">humans</span>
In the small intestine, members of the alpha-defensin family of antimicrobial peptides also require activation through proteolytic removal of an N-terminal prosegment by specific intestinal proteases (2, 9). While trypsin is the processing enzyme for at least one member of the human alpha-defensin family (9), mouse alpha-defensins undergo processing by matrix metalloproteinase-7 (matrilysin; MMP-7) (2). Our findings demonstrate that trypsin coordinately activates multiple innate immune effector proteins in both mice and humans, suggesting that this protease may function as a central regulator of diverse intestinal antibacterial responses in multiple host species.
###end p 55
###begin p 56
###xml 305 307 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 605 607 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
Our results indicate that HIP/PAP prosegment inhibitory activity is governed by interactions between acidic prosegment residues and cationic residues on the remainder of the protein. The prosegments of key intestinal alpha-defensins confer inhibitory activity through a similar charge-charge interaction (20). However, our results suggest that the functional outcome of this interaction is quite different in the two protein families. The alpha-defensin prosegment neutralizes cationic amino acids that bind to negatively charged bacterial phospholipids and are thus essential for antibacterial function (21). In contrast, while HIP/PAP cationic amino acids are required for peptide inhibitory activity, they are dispensable for antibacterial function, indicating that the HIP/PAP prosegment represses antibacterial activity through a distinct mechanism. This is consistent with our finding that RegIIIgamma and HIP/PAP bind to bacterial surfaces through specific recognition of peptidoglycan, and that this binding interaction is not modulated by the prosegment. Collectively, these observations suggest that the RegIII lectins may mediate their antibacterial functions via mechanisms that differ from the alpha-defensins.
###end p 56
###begin p 57
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 1120 1122 1120 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 1124 1125 1124 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1299 1307 1299 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1952 1958 1952 1958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 2103 2105 2103 2105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 2106 2108 2106 2108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 2214 2215 2213 2214 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
NMR spectroscopy has provided structural insight into the HIP/PAP-prosegment interaction. Our analysis revealed a distinctive colinear correspondence between backbone amide shifts as point mutations were made to either side of a putative charge-charge interaction pair. Notably, point mutants with derepressed killing activity demonstrated the greatest degree of chemical shift changes. Such correspondence between structural and functional changes is distinctive, and has previously been observed in several other systems (22-24). The linearity of this behavior further suggests that intramolecular interactions between HIP/PAP and its N-terminal prosegment govern a shift between two states with differing activities. Although the physical basis for this shift is not yet clear, we envision at least three possibilities. One is that disruption of HIP/PAP-prosegment interactions results in allosteric changes in residues that are physically distant from the N terminus. This seems very unlikely given the limited chemical shift changes observed outside the N-terminal region in comparisons of the wildtype and EEE/AAA 15N/1H HSQC spectra. A second possibility is that the activating mutations increase accessibility of the trypsin site to cleavage. However, the lack of HIP/PAP proteolysis in our in vitro antibacterial assays suggests that this is unlikely to explain the enhanced bactericidal activity of the activated pro-HIP/PAP mutants (supplemental Fig. S3). A third possibility is that disruption of the HIP/PAP-prosegment interaction unmasks surfaces on the HIP/PAP core structure that are required for bactericidal activity, and that our chemical shift changes reflect a hinging motion of the prosegment away from the rest of the protein. Such movement could allow the HIP/PAP molecule to adopt an optimal conformation to damage microbial cell surfaces, or could induce formation of multimers that may be required for bactericidal activity (Fig. 8). The latter of these two mechanisms has been observed in other systems in which bactericidal activity requires formation of protein oligomers (25-27). Although our NMR spectra did not show evidence of HIP/PAP multimerization at high concentration (300 mum) in the absence of ligand, it is possible that such association requires both the presence of peptidoglycan ligands and the disruption of HIP/PAP-prosegment interactions.
###end p 57
###begin p 58
###xml 167 172 <span type="species:ncbi:9606">human</span>
In summary, we have uncovered a novel mechanism controlling C-type lectin biological activity. We propose that impaired regulation of RegIII antibacterial activity in human populations could result in compromised intestinal immunity and a predisposition to enteric infections and inflammation. Furthermore, the structural insights from these studies could aid in the design of novel antimicrobial therapeutics.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
[Supplemental Data]
###end title 60
###begin p 61
The abbreviations used are: HIP/PAP, hepatointestinal pancreatic/pancreatitis-associated protein; MES, 4-morpholineethanesulfonic acid; MMP, matrix metalloproteinase.
###end p 61

